J&J's Ethicon gains 510(k) for ultrasonic surgical device; Analogic loses money over medical imaging sales drop;

@FierceMedDev: Echo Therapeutics finds a China partner for its glucose monitor, satisfies an angry investor. Article | Follow @FierceMedDev

@MarkHFierce: Presenting, our latest issue of FierceDiagnostics--check it out, and tell a friend. Issue | Follow @MarkHFierce

@MichaelGFierce: Sanofi's Genzyme nets FDA priority review for its oral Gaucher pill. More from FierceDrugDelivery | Follow @MichaelGFierce

@GalenMoore: Imploding microbubbles give transdermal patch an edge over arthritis. Story | Follow @GalenMoore

> Johnson & Johnson's ($JNJ) Ethicon Endo-Surgery arm won 510(k) clearance for a next-generation ultrasonic surgical shear device. Item

> W.L. Gore won FDA approval to expand the use of its Viabahn Endoprosthesis device to treat hemodialysis patients. Item

> Analogic lost money in its fiscal 2014 first quarter due, in part, to a major drop in medical imaging sales. Item

> Spain's Venter Pharma licensed NovaMedica the rights to market a new diagnostic test for lactose intolerance in Russia. Item

> The market for antimicrobial coatings--which affects medical devices and many other industries--will be worth nearly $3 billion by 2018, according to a new market report. Item

Biotech News

@FierceBiotech: Big Biopharmas help fuel $26M round for Sutro's antibody R&D work. News | Follow @FierceBiotech

@JohnCFierce: GEN ranks VCs by total funds under management. Hmmmm. Feature via GEN | Follow @JohnCFierce

@DamianFierce: With fresh hopes and a bunch of new safety data, Orexigen is going back to the FDA with Contrave. Story | Follow @DamianFierce

@EmilyMFierce: 1 in 100 cancers are associated with a particular gene mutation, according to a Sanger Institute study. Story from FierceBiotech Research  | Follow @EmilyMFierce

> Avanir hits the skids after its pain drug flunks a mid-stage study. More

> Celgene chips in $20M to extend Agios cancer deal. Story

Pharma News

@FiercePharma: Tuesday's best-read new news: Teva braces for $550M hit from Copaxone generics. Story | Follow @FiercePharma

@EricPFierce: The here and now of track and trace. Editor's corner | Follow @EricPFierce

@CarlyHFierce: Tuesday's most popular special report: Top 10 generics makers by 2012 revenue. Report | Follow @CarlyHFierce

> GlaxoSmithKline pledges $330M to ramp up Relvar production, expand in U.K. Story

> Vice president clears way for FDA to add inspectors in China. Article

> Pricey hep C drugs, beware: Express Scripts plans a showdown. More

Diagnostics News

> French company unveils prenatal test based on licensed Sequenom tech. Story

> DioGenix's venture round fuels expanded trial for MS molecular Dx test. Report

> New Hologic CEO pledges to grow, and not sell, the women's health Dx company. More

> Foundation Medicine shows test's worth as a highly specific blood cancer screening tool. Article

> Invitae's $40M Series E adds rocket fuel to genetic test expansion plans. News

> Sequenta expands reach of ultrasensitive cancer Dx test. Item

Biomarkers News

> Biomarker points to aggressive breast cancer in black women. Story

> Cellular switch biomarker predicts prostate cancer's spread. Piece

> In China, lung cancer biomarker testing is on the rise. More

> Gene biomarker may determine whether some depression drugs will work. News

> New tech promises to speed up biomarker validation. Article

> Inflammatory marker presents a new target for obesity drug developers. Item

Drug Delivery News

> Alliqua CEO: Celgene deal vaults us to 'another level of respectability'. Article

> Protein 'crossing guard' carries Alzheimer's drug past the blood-brain barrier. More

> Imploding microbubbles give transdermal patch an edge for arthritis drugs. News

> Sanofi's Genzyme nets FDA priority review for its oral Gaucher pill. Report

> Rutgers team delivers RNA to weaken drug-resistant ovarian cancer. Story

> Swedish team: Omega-3 fatty acids cross blood-brain barrier for possible Alzheimer's treatment. Item

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.